JUPITER NEUROSCIENCES, INC. 8-K

What Happened Jupiter Neurosciences, Inc. filed a Form 8‑K on February 20, 2026 reporting the execution of an Omnibus Amendment to its convertible promissory notes with YA II PN, Ltd. The filing references prior disclosures made in the Company’s “Signing 8‑K” (initially filed October 27, 2025 and amended November 20, 2025) and confirms the amendment is reflected in an exhibit (Omnibus Amendment dated February 20, 2026).

Key Details

• Omnibus Amendment to the convertible promissory notes between Jupiter Neurosciences, Inc. and YA II PN, Ltd., dated February 20, 2026 (filed as Exhibit 4.3).
• The 8‑K cites and incorporates prior filings: the original Signing 8‑K (Oct 27, 2025) and its Nov 20, 2025 amendment.
• Item 2.03: the amendment results in the creation of a direct financial obligation (i.e., modified/continued debt owed to YA II PN, Ltd.).
• Related documents referenced/incorporated by reference include forms of convertible promissory notes, an amended and restated note, and a Standby Equity Purchase Agreement (dated Oct 24, 2025) plus its Nov 19, 2025 amendment.

Why It Matters This 8‑K discloses a material change to Jupiter’s financing arrangements with YA II PN, Ltd., formally documenting changes to its convertible debt obligations. For investors, amendments to promissory notes can affect the company’s balance of debt, future cash requirements, and potential equity dilution if conversion terms are or become relevant. Review the filed Omnibus Amendment (Exhibit 4.3) and the referenced prior 8‑Ks for full terms and any financial detail before drawing conclusions.